Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial. - Naicker V; Laher F; Bekker LG; Seaton KE; Allen M; De Rosa S; Yates NL; Mkhize NN; Saunders K; Heptinstall J; Malahleha M; Mngadi K; et al. (PLOS global public health, 2024)